EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #72932_C
酪氨酸激酶抑制剂；抑制EGFR、HER2、JAK2、JAK3和STAT5a/b
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系
总览
AG-490是酪氨酸激酶小分子抑制剂tyrphostin家族的成员，可抑制包括EGFR （Gazit et al.）、HER2 （Gazit et al.）、JAK2 （Burger et al.）、JAK3 （Brown et al.）和STAT5a/b （Wang et al.）在内的多种酪氨酸激酶，IC₅₀值分别为0.1、13.5、11和12 μM。AG-490不抑制LCK、LYN、BTK、SYK或SRC酪氨酸激酶（Meydan et al.）。
分化
·和LIF和BMP4一起，诱导小鼠（OG2）胚胎干细胞分化（Chen et al.）。
癌症研究
·通过抑制JAK2，诱导程序性细胞死亡，阻断急性淋巴细胞白血病前B细胞的生长（Meydan et al.）。
·抑制宫颈癌细胞系的增殖（Soto-Cruz et al.）。
·抑制 STAT3 磷酸化，并诱导 β-catenin 向结肠癌细胞系 SW480 的胞质转移（Kawada et al.）。
·通过抑制JAK2诱导GL15胶质母细胞瘤细胞的S期阻滞（Sciaccaluga et al.）。
·抑制EGF依赖性NIH3T3细胞系的增殖（Gazit et al.）。
·阻断IL-2诱导的胸腺嘧啶在T细胞系中的结合（Wang et al.）。
细胞类型
癌细胞及细胞系，白血病/淋巴瘤细胞，多能干细胞，T 细胞
种属
人，小鼠，非人灵长类，其它细胞系，大鼠
应用
分化
研究领域
癌症，干细胞生物学
CAS 编号
133550-30-8
化学式
C₁₇H₁₄N₂O₃
纯度
≥98%
通路
JAK/STAT，酪氨酸激酶
靶点
EGFR，HER2，JAK2，JAK3，STAT5
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (2)
文献 (9)
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo Molecular Cancer Therapeutics 2009
Abstract
Protein tyrosine kinases of the Janus kinase (JAK) family are associated with many cytokine receptors, which, on ligand binding, regulate important cellular functions such as proliferation, survival, and differentiation. In multiple myeloma, JAKs may be persistently activated due to a constant stimulation by interleukin (IL)-6, which is produced in the bone marrow environment. INCB20 is a synthetic molecule that potently inhibits all members of the JAK family with a 100- to 1,000-fold selectivity for JAKs over textgreater70 other kinases. Treatment of multiple myeloma cell lines and patient tumor cells with INCB20 resulted in a significant and dose-dependent inhibition of spontaneous as well as IL-6-induced cell growth. Importantly, multiple myeloma cell growth was inhibited in the presence of bone marrow stromal cells. The IL-6 dependent cell line INA-6 was particularly sensitive to the drug (IC50textless1 micromol/L). Growth suppression of INA-6 correlated with an increase in the percentage of apoptotic cells and inhibition of signal transducer and activator of transcription 3 phosphorylation. INCB20 also abrogated the protective effect of IL-6 against dexamethasone by blocking phosphorylation of SHP-2 and AKT. In contrast, AKT phosphorylation induced by insulin-like growth factor-I remained unchanged, showing selectivity of the compound. In a s.c. severe combined immunodeficient mouse model with INA-6, INCB20 significantly delayed INA-6 tumor growth. Our studies show that disruption of JAKs and downstream signaling pathways may both inhibit multiple myeloma cell growth and survival and overcome cytokine-mediated drug resistance, thereby providing the preclinical rationale for the use of JAK inhibitors as a novel therapeutic approach in multiple myeloma.
The Tyrphostin B42 Inhibits Cell Proliferation and HER-2 Autophosphorylation in Cervical Carcinoma Cell Lines Cancer Investigation 2008
Abstract
The HER family receptors have an important role controlling cell growth and differentiation. Although the activity of the HER-2 receptor is strictly controlled in normal cells, its overexpression plays a pivotal role in transformation and tumorigenesis. Constitutive phosphorylation of HER-2 protein has been implicated in conferring uncontrolled growth to mammary cancer cells, and to a lesser extent, with adenocarcinoma of uterus, cervix, fallopian tube, and endometrium. This study addresses the role of HER-2 in cervical carcinoma. Firstly, we demonstrate the presence of HER-2 protein expression by flow cytometry in two new cervical carcinoma cell lines CALO and INBL. Secondly, we use the specific tyrosine kinase inhibitors, Tyrphostins to examine HER-2 regulation by the crystal violet assay. Thirdly, we use western blot analysis to assess the state of HER-2 phosphorylation. The most efficient agent, Tyrphostin B42, known as an inhibitor of epithelial growth factor receptor, arrested cervical carcinoma cell lines growth in vitro at micromolar concentrations within 72 h of application. Tyrphostin B42 inhibited the HER2 signal-regulated kinase pathway, as observed by the reduction in the phosphorylated forms of HER2. The loss of phosphorylated forms of HER2 at early time points after Tyrphostin B42 application was associated with suppression of cell growth. Thus, the inhibition of the proliferation of our cervical carcinoma cell lines by Tyrphostin B42 is associated with inhibition of HER2 protein kinase signal.
Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line. Oncology reports 2007
Abstract
The notion that gliomas could originate from mutated glial precursor cells highlights the possibility of modulating the proliferative and migratory behaviour of glioma cells by acting on the molecular mechanisms operative during the development of the Central Nervous System (CNS), but absent in the normal adult brain. We show that the GL15 glioblastoma derived human cell line displays a high expression of nestin which, combined with the previously demonstrated high expression of vimentin, constitutes a characteristic of astrocyte restricted precursors. We also show that, in analogy with some leukaemia cells, GL15 cells display the constitutively phosphorylated form of Janus kinase 2 (JAK2), a tyrosine kinase expressed during CNS development but undetectable in the normal adult brain. The constitutive activation of JAK2 does not result from chromosomal aberrations involving the JAK2 gene, but most probably from abnormally activated transduction systems operative in glioblastoma cells. We then investigated the effects of tyrphostin AG490, an inhibitor of JAK2 autophosphorylation, on GL15 cell growth. In the absence of exogenous growth factors and cytokines, 10 microM tyrphostin AG490 induces an S phase arrest, combined with a partial impairment of the G2 phase of the cell cycle. The abnormally activated JAK2 could then potentially represent a target for a selective pharmacological approach in glioblastoma cells in which a combination of glial precursor characteristics and genetic alterations occurs.
更多信息
| 种属 | Human, Mouse, Non-Human Primate, Other, Rat |
|---|---|
| Cas Number | 133550-30-8 |
| Chemical Formula | C₁₇H₁₄N₂O₃ |
| 纯度 | ≥ 98% |
| Target | EGFR, HER2, JAK2, JAK3, STAT5 |
| Pathway | JAK/STAT, Tyrosine Kinase |
相关产品
-
拉帕替尼酪氨酸激酶抑制剂；抑制EGFR和HER2
-
SU5416酪氨酸激酶抑制剂；抑制KDR、PDGFR、KIT、RET、FLT-3、ABL、ALK
-
Vandetanib酪氨酸激酶抑制剂；抑制VEGFR1、KDR、FLT-4、EGFR、FGFR、ABL、RET和SRC
-
重组小鼠LIF白血病抑制因子
